Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Apraziquantel

Phase 2Small molecule

JJennifer Keiser

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Opisthorchis ViverriniRecruiting

Opisthorchis ViverriniPhase 2

Recruiting

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Opisthorchis Viverrini

NCT07262814

Clinical

Trials by Indication[1]

Opisthorchis Viverrini1 trial

Efficacy, Safety and Acceptability of Ascending Doses of Arpraziquantel for Opisthorchis Viverrini Infections in Children Aged 6-7 Years: A Single-blind Randomized Dose-ranging Trial

Recruiting·JJennifer Keiser·Phase 2·NCT07262814·125 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Apraziquantel. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Apraziquantel compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Apraziquantel. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Jennifer Keiser company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: JJennifer Keiser

Related News